{"gene":"GSTM1","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2009,"finding":"The GSTM1 promoter contains a functional polymorphism that alters binding of the AP-2alpha transcription factor, resulting in reduced promoter activity and mRNA expression. A U-shaped (non-linear) association was identified: both GSTM1 null (no copies) and GSTM1 homozygous wild-type (+/+, two copies) are risk genotypes for breast cancer compared to heterozygous (+/-), suggesting that approximately 60-70% GSTM1 expression from one allele is sufficient for protection, and that both null activity and overactivity are disadvantageous.","method":"Case-control genotyping with copy-number distinction (null/heterozygous/homozygous), meta-analysis of 41 studies, reporter/promoter activity assay, electrophoretic mobility shift assay (AP-2alpha binding), and mRNA expression measurement","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (functional promoter assay, transcription factor binding, expression, population genetics) in a single lab; no independent replication of the mechanistic promoter finding reported in the corpus","pmids":["19228880"],"is_preprint":false},{"year":2009,"finding":"GSTM1 copy number varies in a population-specific manner: more than 75% of Caucasian (CEU) HapMap samples carry a GSTM1 deletion, and none have two copies, whereas up to 25% of African (YRI) samples carry two copies of GSTM1. A previously reported HapMap SNP (rs366631) is a pseudo-SNP arising from sequence homology and the common GSTM1 upstream deletion; the upstream deletion can serve as a marker of GSTM1 gene deletion.","method":"Site-specific genotyping assays, copy-number variation (CNV) assays covering three GSTM1 regions, genome-wide association with expression in HapMap lymphoblastoid cell lines","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple CNV assays across gene regions, functional link to expression established by GWA; single lab, no independent replication cited","pmids":["18948376"],"is_preprint":false},{"year":2019,"finding":"The GSTM1 promoter is significantly hypomethylated in ectopic and eutopic endometrium of ovarian endometriosis patients compared to controls, and this hypomethylation correlates negatively with GSTM1 mRNA expression. In vitro overexpression of GSTM1 in endometrial epithelial cells significantly increased cell viability and inhibited apoptosis following hormone treatment and withdrawal, demonstrating a functional anti-apoptotic role for GSTM1 in endometrial cells.","method":"Pyrosequencing of GSTM1 promoter methylation, RT-qPCR and immunohistochemistry for expression, primary endometrial epithelial cell culture with GSTM1 transfection, Cell Counting Kit-8 viability assay, flow cytometry for apoptosis","journal":"Human reproduction (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (bisulfite pyrosequencing, expression, functional overexpression in primary cells) in a single lab; anti-apoptotic function demonstrated by loss/gain in vitro but no independent replication","pmids":["30989213"],"is_preprint":false},{"year":2012,"finding":"GSTM1 (glutathione S-transferase Mu 1) plays a protective role in lung inflammation; its expression is regulated by the NF-E2-related factor 2 (Nrf2) transcription factor pathway, and GSTM1 acts through interactions with other genes and environmental factors (especially air pollutants) to modulate pulmonary inflammatory responses. The GSTM1 null polymorphism (high prevalence in the population) is associated with increased risk of inflammatory lung diseases.","method":"Review synthesizing epidemiological, clinical, animal, and in vitro studies; no single primary experiment described in the abstract","journal":"Free radical biology & medicine","confidence":"Low","confidence_rationale":"Tier 4 / Weak — review/synthesis paper; no primary experiment described in the abstract to directly establish Nrf2 regulation or specific inflammatory mechanism for GSTM1","pmids":["22683820"],"is_preprint":false},{"year":2004,"finding":"GSTM1 is involved in the metabolic detoxification of hydroquinone (a benzene metabolite): human lymphocytes from donors with the GSTM1 null genotype showed significantly higher micronucleus frequency upon hydroquinone treatment compared to GSTM1-present donors, indicating that GSTM1 status determines inter-individual differences in genotoxic DNA damage from hydroquinone exposure.","method":"Ex vivo treatment of human lymphocytes from genotyped donors with hydroquinone; micronucleus (MN) and sister-chromatid exchange (SCE) assays; genotyping of GSTM1, GSTT1, GSTP1","journal":"Environmental and molecular mutagenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay directly linking GSTM1 genotype to hydroquinone-induced DNA damage in human lymphocytes, two genotoxicity endpoints, single lab","pmids":["15141365"],"is_preprint":false},{"year":2002,"finding":"GSTM1 genotype modifies benzo[a]pyrene diol epoxide (BPDE)-DNA adduct levels in human lung: GSTM1*0 (null) individuals have higher (+)-anti-BPDE-DNA adduct levels in lung parenchyma than GSTM1-positive individuals. Carriers of the combined CYP1A1*2/GSTM1*0 genotype have the highest adduct levels, consistent with GSTM1 functioning to detoxify BPDE formed by CYP1A1-mediated activation of benzo[a]pyrene.","method":"Review and synthesis of published human lung tissue data measuring (+)-anti-BPDE-DNA adducts by immunoassay, stratified by CYP1A1 and GSTM1 genotype","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — convergent human tissue adduct data across multiple published studies; review synthesis rather than single primary experiment, but mechanistic inference is directly supported by adduct measurements","pmids":["12507920"],"is_preprint":false},{"year":2010,"finding":"GSTM1 null genotype combined with NAT2 slow acetylator genotype synergistically increases carcinogen DNA adduct levels in human lung tissue by approximately 295% over baseline, compared to 150% for GSTM1 null alone and ~74% for NAT2 slow alone, demonstrating that GSTM1 and NAT2 act independently and interactively in protecting lung tissue from carcinogen adduct formation.","method":"(32)P-postlabeling assay for DNA adducts in lung and blood tissue from lung cancer patients; multiple regression analysis adjusting for confounders and other GST variants","journal":"Cancer epidemiology, biomarkers & prevention","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct tissue adduct measurement in human lung with quantitative genotype-stratified analysis; single study, single method for adduct quantification","pmids":["20501762"],"is_preprint":false},{"year":1997,"finding":"GSTM1 null genotype is associated with higher CYP1A2 activity (measured by caffeine phenotyping) compared to GSTM1*A,B individuals (10.2 vs. 8.5 under unexposed conditions; 15.0 vs. 12.3 under exposed conditions), indicating a gene-gene interaction whereby GSTM1 genotype influences in vivo CYP1A2 function.","method":"Caffeine phenotyping for CYP1A2 activity (urinary molar ratio), PCR-based GSTM1 and CYP1A1 genotyping in human volunteers under controlled dietary/smoking exposures","journal":"Mutation research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — indirect phenotyping assay, single lab, small samples, mechanism of interaction not directly elucidated","pmids":["9202749"],"is_preprint":false},{"year":2013,"finding":"GSTM1 null genotype is associated with significantly increased urinary markers of oxidative DNA damage (8-OHdG) and lipid peroxidation (8-epi-PGF2α) in bladder cancer patients, and GSTM1-null combined with GSTA1-low activity genotype further amplifies oxidative DNA damage (8-OHdG), indicating GSTM1 functions as an antioxidant defense enzyme protecting against oxidative damage in bladder tissue.","method":"Enzyme immunoassay for 8-OHdG and 8-epi-PGF2α in urine of 80 TCC patients and 60 controls; PCR genotyping for GSTM1 deletion; PCR-RFLP for GSTA1 SNP","journal":"Redox report : communications in free radical research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — genotype-phenotype association using biomarker endpoints; single lab, single study, no direct enzymatic manipulation","pmids":["23394311"],"is_preprint":false},{"year":2007,"finding":"In women with GSTM1 null genotype, arsenic exposure (measured by urinary arsenic) was significantly associated with increased urinary 8-OHdG (a marker of oxidative DNA damage), whereas no such association was seen in GSTM1-positive women, demonstrating that GSTM1 protects against arsenic-induced oxidative stress.","method":"Repeated-measures cohort study; urinary 8-OHdG measurement; arsenic exposure measured in urine, toenails, and drinking water; Taqman genotyping of GSTM1; random-effects Tobit regression","journal":"Environmental health : a global access science source","confidence":"Low","confidence_rationale":"Tier 3 / Weak — indirect biomarker association study; repeated measures add rigor but mechanism is inferred from genotype-exposure interaction, not direct enzyme assay","pmids":["18053222"],"is_preprint":false}],"current_model":"GSTM1 encodes a glutathione S-transferase that catalyzes conjugation of glutathione with electrophilic compounds including polycyclic aromatic hydrocarbon metabolites (e.g., BPDE) and hydroquinone, thereby protecting cells from carcinogen-induced DNA adduct formation and oxidative DNA damage; its expression is regulated epigenetically (promoter methylation) and transcriptionally (AP-2alpha binding to a promoter polymorphism), and it exhibits a non-linear gene-dosage effect on cancer risk; in endometrial epithelial cells, GSTM1 overexpression directly inhibits apoptosis and promotes cell survival; the common homozygous deletion (null) genotype, which varies in frequency across populations, abolishes enzyme activity and increases susceptibility to DNA damage from environmental carcinogens and oxidative stress."},"narrative":{"mechanistic_narrative":"GSTM1 encodes a glutathione S-transferase that protects cells from electrophilic carcinogens and oxidative stress, and its activity is a major determinant of inter-individual susceptibility to DNA damage [PMID:12507920, PMID:20501762]. Functionally, GSTM1 detoxifies reactive metabolites: it conjugates the benzene metabolite hydroquinone, with null-genotype lymphocytes showing elevated genotoxic micronucleus frequency upon hydroquinone exposure [PMID:15141365], and it neutralizes benzo[a]pyrene diol epoxide (BPDE) generated by CYP1A1, such that null individuals accumulate higher BPDE-DNA adducts in lung tissue [PMID:12507920]. This protective role extends beyond electrophile conjugation to antioxidant defense, as the null genotype is associated with increased oxidative DNA damage markers (8-OHdG) under carcinogen and arsenic exposure [PMID:23394311, PMID:18053222]. GSTM1 acts within a network of xenobiotic-metabolizing genes, interacting independently and synergistically with NAT2 to limit carcinogen adduct formation [PMID:20501762] and influencing in vivo CYP1A2 activity [PMID:9202749]. GSTM1 expression is shaped by a promoter polymorphism that modulates AP-2alpha binding, producing a non-linear (U-shaped) gene-dosage effect in which both null and high-expression genotypes are disadvantageous [PMID:19228880], and by promoter methylation, with hypomethylation-driven overexpression conferring an anti-apoptotic, pro-survival function in endometrial epithelial cells [PMID:30989213]. The common homozygous deletion (null) genotype, whose frequency varies markedly across populations, abolishes enzyme activity [PMID:18948376].","teleology":[{"year":1997,"claim":"Established that GSTM1 genotype is not isolated but influences the activity of other xenobiotic-metabolizing enzymes, hinting at a coordinated detoxification network.","evidence":"Caffeine phenotyping for CYP1A2 activity with PCR genotyping in human volunteers under controlled exposures","pmids":["9202749"],"confidence":"Low","gaps":["Indirect phenotyping assay with small samples","Mechanism linking GSTM1 status to CYP1A2 activity not elucidated"]},{"year":2002,"claim":"Demonstrated that GSTM1 detoxifies CYP1A1-activated benzo[a]pyrene, with null genotype yielding higher BPDE-DNA adducts in lung, defining a concrete carcinogen substrate pathway.","evidence":"Synthesis of human lung tissue (+)-anti-BPDE-DNA adduct immunoassay data stratified by CYP1A1 and GSTM1 genotype","pmids":["12507920"],"confidence":"Medium","gaps":["Review synthesis rather than single controlled experiment","Direct enzymatic conjugation of BPDE by GSTM1 not assayed in vitro here"]},{"year":2004,"claim":"Provided direct functional evidence that GSTM1 protects against genotoxic damage from a specific substrate, hydroquinone, in primary human cells.","evidence":"Ex vivo hydroquinone treatment of genotyped human lymphocytes with micronucleus and sister-chromatid exchange assays","pmids":["15141365"],"confidence":"Medium","gaps":["Genotype-based comparison rather than direct enzyme knockdown/rescue","Single lab"]},{"year":2009,"claim":"Resolved the regulatory basis and dosage relationship of GSTM1 expression, identifying an AP-2alpha-binding promoter polymorphism and a non-linear U-shaped risk effect.","evidence":"Case-control copy-number genotyping, meta-analysis, reporter assay, EMSA for AP-2alpha binding, and mRNA measurement","pmids":["19228880"],"confidence":"Medium","gaps":["Promoter mechanism not independently replicated","Why high expression is disadvantageous not mechanistically explained"]},{"year":2009,"claim":"Defined the population-specific copy-number architecture of GSTM1 and corrected a spurious marker SNP, establishing the deletion as the functional driver of expression differences.","evidence":"Site-specific and CNV genotyping assays with genome-wide expression association in HapMap lymphoblastoid lines","pmids":["18948376"],"confidence":"Medium","gaps":["No independent replication cited","Functional consequence beyond expression not assessed in this work"]},{"year":2010,"claim":"Quantified how GSTM1 cooperates with NAT2 to limit carcinogen DNA adduct burden, showing independent and synergistic protective contributions.","evidence":"32P-postlabeling DNA adduct measurement in human lung tissue with genotype-stratified multiple regression","pmids":["20501762"],"confidence":"Medium","gaps":["Single study and single adduct quantification method","Molecular basis of GSTM1-NAT2 synergy not resolved"]},{"year":2013,"claim":"Extended GSTM1's protective role from electrophile conjugation to antioxidant defense, linking null genotype to elevated oxidative DNA damage in bladder tissue.","evidence":"Enzyme immunoassay for urinary 8-OHdG and 8-epi-PGF2alpha in bladder cancer patients with PCR genotyping","pmids":["23394311"],"confidence":"Low","gaps":["Biomarker association without direct enzymatic manipulation","Single lab/study"]},{"year":2019,"claim":"Uncovered a non-detoxification cellular function: methylation-driven GSTM1 overexpression suppresses apoptosis and promotes survival in endometrial epithelial cells.","evidence":"Promoter methylation pyrosequencing, expression analysis, and GSTM1 overexpression in primary endometrial cells with viability and apoptosis assays","pmids":["30989213"],"confidence":"Medium","gaps":["Anti-apoptotic mechanism (effectors, signaling) not defined","No independent replication"]},{"year":null,"claim":"How GSTM1's enzymatic detoxification activity mechanistically connects to its anti-apoptotic, pro-survival role, and why high expression confers risk, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural or kinetic model linking conjugation activity to survival signaling","Mechanism of the U-shaped dosage effect uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[4,5]},{"term_id":"GO:0016209","term_label":"antioxidant activity","supporting_discovery_ids":[8,9]}],"localization":[],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[4,5,6]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09488","full_name":"Glutathione S-transferase Mu 1","aliases":["GST HB subunit 4","GST class-mu 1","GSTM1-1","GSTM1a-1a","GSTM1b-1b","GTH4"],"length_aa":218,"mass_kda":25.7,"function":"Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2) (PubMed:9084911). Participates in the formation of novel hepoxilin regioisomers (PubMed:21046276)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P09488/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GSTM1","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1090,"dependency_fraction":0.003669724770642202},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GSTM1","total_profiled":1310},"omim":[{"mim_id":"620557","title":"IQ MOTIF- AND UBIQUITIN DOMAIN-CONTAINING PROTEIN; IQUB","url":"https://www.omim.org/entry/620557"},{"mim_id":"606963","title":"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; COPD","url":"https://www.omim.org/entry/606963"},{"mim_id":"600859","title":"AMINOACYL tRNA SYNTHETASE COMPLEX-INTERACTING MULTIFUNCTIONAL PROTEIN 2; AIMP2","url":"https://www.omim.org/entry/600859"},{"mim_id":"600436","title":"GLUTATHIONE S-TRANSFERASE, THETA-1; GSTT1","url":"https://www.omim.org/entry/600436"},{"mim_id":"211980","title":"LUNG CANCER","url":"https://www.omim.org/entry/211980"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Microtubules","reliability":"Additional"},{"location":"Cytokinetic bridge","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Primary cilium transition zone","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":569.8}],"url":"https://www.proteinatlas.org/search/GSTM1"},"hgnc":{"alias_symbol":["MU","H-B"],"prev_symbol":["GST1"]},"alphafold":{"accession":"P09488","domains":[{"cath_id":"3.40.30.10","chopping":"2-84","consensus_level":"medium","plddt":98.4418,"start":2,"end":84},{"cath_id":"1.20.1050.10","chopping":"90-191","consensus_level":"medium","plddt":98.3773,"start":90,"end":191}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09488","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09488-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09488-F1-predicted_aligned_error_v6.png","plddt_mean":98.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GSTM1","jax_strain_url":"https://www.jax.org/strain/search?query=GSTM1"},"sequence":{"accession":"P09488","fasta_url":"https://rest.uniprot.org/uniprotkb/P09488.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09488/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09488"}},"corpus_meta":[{"pmid":"9809991","id":"PMC_9809991","title":"Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9809991","citation_count":211,"is_preprint":false},{"pmid":"9367063","id":"PMC_9367063","title":"Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer.","date":"1997","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9367063","citation_count":160,"is_preprint":false},{"pmid":"12507920","id":"PMC_12507920","title":"CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation.","date":"2002","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12507920","citation_count":132,"is_preprint":false},{"pmid":"10739168","id":"PMC_10739168","title":"Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms.","date":"2000","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10739168","citation_count":126,"is_preprint":false},{"pmid":"18270371","id":"PMC_18270371","title":"Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis.","date":"2008","source":"American journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/18270371","citation_count":121,"is_preprint":false},{"pmid":"12016153","id":"PMC_12016153","title":"Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population.","date":"2002","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12016153","citation_count":106,"is_preprint":false},{"pmid":"9276626","id":"PMC_9276626","title":"Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms and lung cancer risk among Northwestern Mediterraneans.","date":"1997","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/9276626","citation_count":101,"is_preprint":false},{"pmid":"11159742","id":"PMC_11159742","title":"GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer.","date":"2001","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11159742","citation_count":100,"is_preprint":false},{"pmid":"20183528","id":"PMC_20183528","title":"Genetic Polymorphism in Glutathione Transferases (GST): Population distribution of GSTM1, T1, and P1 conjugating activity.","date":"2009","source":"Journal of toxicology and environmental health. Part B, Critical reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20183528","citation_count":99,"is_preprint":false},{"pmid":"10753202","id":"PMC_10753202","title":"CYP1A1 and GSTM1 polymorphisms affect urinary 1-hydroxypyrene levels after PAH exposure.","date":"2000","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/10753202","citation_count":89,"is_preprint":false},{"pmid":"11872636","id":"PMC_11872636","title":"Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer.","date":"2002","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11872636","citation_count":76,"is_preprint":false},{"pmid":"12175548","id":"PMC_12175548","title":"GSTM1, GSTT1 and GSTP1 polymorphisms and lung cancer risk.","date":"2002","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12175548","citation_count":73,"is_preprint":false},{"pmid":"10952100","id":"PMC_10952100","title":"Lung cancer risk in nonsmokers and GSTM1 and GSTT1 genetic polymorphism.","date":"2000","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10952100","citation_count":73,"is_preprint":false},{"pmid":"18398695","id":"PMC_18398695","title":"Genetic polymorphisms of GSTO2, GSTM1, and GSTT1 and risk of gastric cancer.","date":"2008","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/18398695","citation_count":70,"is_preprint":false},{"pmid":"20563854","id":"PMC_20563854","title":"GSTT1 and GSTM1 gene polymorphisms in European and African populations.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/20563854","citation_count":68,"is_preprint":false},{"pmid":"9329643","id":"PMC_9329643","title":"Influence of GSTM1 and NAT2 genotypes on placental DNA adducts in an environmentally exposed population.","date":"1997","source":"Environmental and molecular mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/9329643","citation_count":60,"is_preprint":false},{"pmid":"18848868","id":"PMC_18848868","title":"NQO1, MPO, CYP2E1, GSTT1 and GSTM1 polymorphisms and biological effects of benzene exposure--a literature review.","date":"2008","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/18848868","citation_count":59,"is_preprint":false},{"pmid":"9202749","id":"PMC_9202749","title":"Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2.","date":"1997","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/9202749","citation_count":58,"is_preprint":false},{"pmid":"9066737","id":"PMC_9066737","title":"GSTM1 gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers.","date":"1997","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/9066737","citation_count":58,"is_preprint":false},{"pmid":"17461521","id":"PMC_17461521","title":"Polymorphisms of CYP1A1 and GSTM1 genes and susceptibility to oral cancer.","date":"2007","source":"Yonsei medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17461521","citation_count":57,"is_preprint":false},{"pmid":"14534704","id":"PMC_14534704","title":"Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk.","date":"2003","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/14534704","citation_count":56,"is_preprint":false},{"pmid":"11833070","id":"PMC_11833070","title":"Relationship of tobacco smoking CYP1A1 GSTM1 gene polymorphism and esophageal cancer in Xi'an.","date":"2002","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/11833070","citation_count":53,"is_preprint":false},{"pmid":"18159984","id":"PMC_18159984","title":"Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking.","date":"2007","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/18159984","citation_count":52,"is_preprint":false},{"pmid":"9150753","id":"PMC_9150753","title":"DNA adducts in human placenta as related to air pollution and to GSTM1 genotype.","date":"1997","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/9150753","citation_count":50,"is_preprint":false},{"pmid":"10607733","id":"PMC_10607733","title":"GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients.","date":"2000","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/10607733","citation_count":49,"is_preprint":false},{"pmid":"20568049","id":"PMC_20568049","title":"GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.","date":"2010","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/20568049","citation_count":46,"is_preprint":false},{"pmid":"22952149","id":"PMC_22952149","title":"Relevance of GSTM1, GSTT1, and GSTP1 gene polymorphisms to gastric cancer susceptibility and phenotype.","date":"2012","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22952149","citation_count":44,"is_preprint":false},{"pmid":"16030123","id":"PMC_16030123","title":"GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma.","date":"2005","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16030123","citation_count":44,"is_preprint":false},{"pmid":"19228880","id":"PMC_19228880","title":"A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer.","date":"2009","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/19228880","citation_count":44,"is_preprint":false},{"pmid":"17693660","id":"PMC_17693660","title":"Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17693660","citation_count":42,"is_preprint":false},{"pmid":"10597978","id":"PMC_10597978","title":"GSTM1, smoking and lung cancer: a case-control study.","date":"1999","source":"International journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/10597978","citation_count":40,"is_preprint":false},{"pmid":"15579657","id":"PMC_15579657","title":"Maternal genetic polymorphisms in CYP1A1, GSTM1 and GSTT1 and the risk of hypospadias.","date":"2004","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/15579657","citation_count":40,"is_preprint":false},{"pmid":"16869871","id":"PMC_16869871","title":"GSTM1 and GSTT1 null genotypes as possible heritable factors of rosacea.","date":"2006","source":"Photodermatology, photoimmunology & photomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/16869871","citation_count":40,"is_preprint":false},{"pmid":"21385088","id":"PMC_21385088","title":"CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer among Lebanese.","date":"2011","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/21385088","citation_count":39,"is_preprint":false},{"pmid":"10720475","id":"PMC_10720475","title":"GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10720475","citation_count":39,"is_preprint":false},{"pmid":"18628429","id":"PMC_18628429","title":"GSTM1 and GSTT1 gene deletions and the risk for nasopharyngeal carcinoma in Han Chinese.","date":"2008","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18628429","citation_count":38,"is_preprint":false},{"pmid":"15588859","id":"PMC_15588859","title":"Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India.","date":"2005","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15588859","citation_count":38,"is_preprint":false},{"pmid":"12150456","id":"PMC_12150456","title":"GSTM1 and GSTT1 polymorphisms and postmenopausal breast cancer risk.","date":"2002","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/12150456","citation_count":37,"is_preprint":false},{"pmid":"19811334","id":"PMC_19811334","title":"Meta-analysis study of glutathione-S-transferases (GSTM1, GSTP1, and GSTT1) gene polymorphisms and risk of acute myeloid leukemia.","date":"2009","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/19811334","citation_count":37,"is_preprint":false},{"pmid":"11173863","id":"PMC_11173863","title":"Susceptibility genes: GSTM1 and GSTM3 as genetic risk factors in bladder cancer.","date":"2000","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11173863","citation_count":37,"is_preprint":false},{"pmid":"33990973","id":"PMC_33990973","title":"Association of GSTM1 and GSTT1 gene polymorphisms with COVID-19 susceptibility and its outcome.","date":"2021","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/33990973","citation_count":36,"is_preprint":false},{"pmid":"22683820","id":"PMC_22683820","title":"Role of GSTM1 in resistance to lung inflammation.","date":"2012","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22683820","citation_count":36,"is_preprint":false},{"pmid":"21736951","id":"PMC_21736951","title":"Genetic polymorphisms of GSTM1, GSTT1 and GSTP1 and susceptibility to DNA damage in workers occupationally exposed to organophosphate pesticides.","date":"2011","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/21736951","citation_count":36,"is_preprint":false},{"pmid":"20853551","id":"PMC_20853551","title":"GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs.","date":"2010","source":"Journal of clinical pharmacy and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20853551","citation_count":35,"is_preprint":false},{"pmid":"20878561","id":"PMC_20878561","title":"Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility.","date":"2010","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20878561","citation_count":35,"is_preprint":false},{"pmid":"14662415","id":"PMC_14662415","title":"GSTM1 polymorphism and oral squamous cell carcinoma.","date":"2004","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14662415","citation_count":32,"is_preprint":false},{"pmid":"15004652","id":"PMC_15004652","title":"Polymorphisms at GSTM1 and GSTT1 gene loci and susceptibility to cervical cancer in Indian population.","date":"2004","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/15004652","citation_count":32,"is_preprint":false},{"pmid":"16614107","id":"PMC_16614107","title":"GSTM1 and CYP1A1 polymorphisms, tobacco, air pollution, and lung cancer: a study in rural Thailand.","date":"2006","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16614107","citation_count":31,"is_preprint":false},{"pmid":"16830058","id":"PMC_16830058","title":"Genetic polymorphism at GSTM1 and GSTT1 gene loci and susceptibility to oral cancer.","date":"2006","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/16830058","citation_count":31,"is_preprint":false},{"pmid":"15141365","id":"PMC_15141365","title":"GSTM1, GSTT1, and GSTP1 genotypes and the genotoxicity of hydroquinone in human lymphocytes.","date":"2004","source":"Environmental and molecular mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/15141365","citation_count":30,"is_preprint":false},{"pmid":"18948376","id":"PMC_18948376","title":"Population-specific GSTM1 copy number variation.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18948376","citation_count":30,"is_preprint":false},{"pmid":"28720685","id":"PMC_28720685","title":"The Loss of GSTM1 Associates with Kidney Failure and Heart Failure.","date":"2017","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/28720685","citation_count":29,"is_preprint":false},{"pmid":"12944179","id":"PMC_12944179","title":"Interaction between smoking, GSTM1 deletion and colorectal cancer: results from the GSEC study.","date":"2003","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/12944179","citation_count":27,"is_preprint":false},{"pmid":"26552558","id":"PMC_26552558","title":"GSTA1, GSTM1, GSTP1 and GSTT1 polymorphisms in progressive myoclonus epilepsy: A Serbian case-control study.","date":"2015","source":"Seizure","url":"https://pubmed.ncbi.nlm.nih.gov/26552558","citation_count":27,"is_preprint":false},{"pmid":"12716303","id":"PMC_12716303","title":"Polymorphism in GSTM1, GSTT1, and GSTP1 and Susceptibility to Lung Cancer in a Japanese Population.","date":"2000","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/12716303","citation_count":27,"is_preprint":false},{"pmid":"18053222","id":"PMC_18053222","title":"GSTM1 and APE1 genotypes affect arsenic-induced oxidative stress: a repeated measures study.","date":"2007","source":"Environmental health : a global access science source","url":"https://pubmed.ncbi.nlm.nih.gov/18053222","citation_count":26,"is_preprint":false},{"pmid":"11501853","id":"PMC_11501853","title":"Genetic polymorphisms of CYP1A1 and GSTM1 and lung cancer risk.","date":"2001","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11501853","citation_count":26,"is_preprint":false},{"pmid":"19856098","id":"PMC_19856098","title":"Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1.","date":"2009","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/19856098","citation_count":25,"is_preprint":false},{"pmid":"14688020","id":"PMC_14688020","title":"Diet, GSTM1 and GSTT1 and head and neck cancer.","date":"2003","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/14688020","citation_count":24,"is_preprint":false},{"pmid":"22575983","id":"PMC_22575983","title":"Meta-analysis of association between GSTM1 gene polymorphism and cervical cancer.","date":"2012","source":"Asian Pacific journal of tropical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22575983","citation_count":24,"is_preprint":false},{"pmid":"26125851","id":"PMC_26125851","title":"Polymorphisms in GSTM1, GSTT1, GSTP1, and GSTM3 genes and breast cancer risk in northeastern Mexico.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26125851","citation_count":24,"is_preprint":false},{"pmid":"36112350","id":"PMC_36112350","title":"Worldwide Systematic Review of GSTM1 and GSTT1 Null Genotypes by Continent, Ethnicity, and Therapeutic Area.","date":"2022","source":"Omics : a journal of integrative biology","url":"https://pubmed.ncbi.nlm.nih.gov/36112350","citation_count":23,"is_preprint":false},{"pmid":"20036620","id":"PMC_20036620","title":"GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans.","date":"2009","source":"Tuberculosis (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/20036620","citation_count":23,"is_preprint":false},{"pmid":"26295386","id":"PMC_26295386","title":"Genetic Polymorphisms of Glutathione-Related Enzymes (GSTM1, GSTT1, and GSTP1) and Schizophrenia Risk: A Meta-Analysis.","date":"2015","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26295386","citation_count":22,"is_preprint":false},{"pmid":"30519912","id":"PMC_30519912","title":"Genotoxicity of inhalational anesthetics and its relationship with the polymorphisms of GSTT1, GSTM1, and GSTP1 genes.","date":"2018","source":"Environmental science and pollution research international","url":"https://pubmed.ncbi.nlm.nih.gov/30519912","citation_count":22,"is_preprint":false},{"pmid":"20501762","id":"PMC_20501762","title":"Synergistic effects of NAT2 slow and GSTM1 null genotypes on carcinogen DNA damage in the lung.","date":"2010","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20501762","citation_count":22,"is_preprint":false},{"pmid":"21458313","id":"PMC_21458313","title":"GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer.","date":"2011","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21458313","citation_count":21,"is_preprint":false},{"pmid":"30989213","id":"PMC_30989213","title":"Hypomethylation of the GSTM1 promoter is associated with ovarian endometriosis.","date":"2019","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30989213","citation_count":20,"is_preprint":false},{"pmid":"20370484","id":"PMC_20370484","title":"Association of GSTM1 and GSTT1 gene deletions with susceptibility to DNA damage in the pesticide-exposed workers of Punjab.","date":"2010","source":"Rejuvenation research","url":"https://pubmed.ncbi.nlm.nih.gov/20370484","citation_count":20,"is_preprint":false},{"pmid":"23394311","id":"PMC_23394311","title":"GSTM1-null and GSTA1-low activity genotypes are associated with enhanced oxidative damage in bladder cancer.","date":"2013","source":"Redox report : communications in free radical research","url":"https://pubmed.ncbi.nlm.nih.gov/23394311","citation_count":20,"is_preprint":false},{"pmid":"26407578","id":"PMC_26407578","title":"Relevance of GSTM1, GSTT1 and GSTP1 Gene Polymorphism to Breast Cancer Susceptibility in Mizoram Population, Northeast India.","date":"2015","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26407578","citation_count":20,"is_preprint":false},{"pmid":"23725116","id":"PMC_23725116","title":"Deletion of GSTM1 and T1 genes as a risk factor for development of acute leukemia.","date":"2013","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/23725116","citation_count":20,"is_preprint":false},{"pmid":"25640380","id":"PMC_25640380","title":"Distributions of the GSTM1 and GSTT1 null genotypes worldwide are characterized by latitudinal clines.","date":"2015","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25640380","citation_count":19,"is_preprint":false},{"pmid":"24903797","id":"PMC_24903797","title":"Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.","date":"2014","source":"The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease","url":"https://pubmed.ncbi.nlm.nih.gov/24903797","citation_count":19,"is_preprint":false},{"pmid":"18303971","id":"PMC_18303971","title":"Glutathione S-transferase GSTT1 and GSTM1 allozymes: beyond null alleles.","date":"2008","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/18303971","citation_count":19,"is_preprint":false},{"pmid":"25249451","id":"PMC_25249451","title":"Association of DCC, MLH1, GSTT1, GSTM1, and TP53 gene polymorphisms with colorectal cancer in Kazakhstan.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25249451","citation_count":18,"is_preprint":false},{"pmid":"16938565","id":"PMC_16938565","title":"Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk.","date":"2006","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16938565","citation_count":18,"is_preprint":false},{"pmid":"20676536","id":"PMC_20676536","title":"GSTM1 and GSTT1 genes analysis in head and neck cancer patients.","date":"2010","source":"Revista da Associacao Medica Brasileira (1992)","url":"https://pubmed.ncbi.nlm.nih.gov/20676536","citation_count":17,"is_preprint":false},{"pmid":"29765533","id":"PMC_29765533","title":"GSTM1, GSTT1, and GSTP1 polymorphisms and colorectal cancer risk in Polish nonsmokers.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29765533","citation_count":17,"is_preprint":false},{"pmid":"22783438","id":"PMC_22783438","title":"Correlation of CYP1A1, GSTP1 and GSTM1 gene polymorphisms and lung cancer risk among smokers.","date":"2012","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/22783438","citation_count":17,"is_preprint":false},{"pmid":"20942828","id":"PMC_20942828","title":"Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.","date":"2010","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/20942828","citation_count":17,"is_preprint":false},{"pmid":"20526719","id":"PMC_20526719","title":"GSTM1, GSTP1, and NQO1 polymorphisms and susceptibility to atopy and airway hyperresponsiveness among South African schoolchildren.","date":"2010","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/20526719","citation_count":17,"is_preprint":false},{"pmid":"19259333","id":"PMC_19259333","title":"CYP1A1, mEH, and GSTM1 Polymophisms and Risk of Oral and Pharyngeal Cancer: A Spanish Case-Control Study.","date":"2008","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19259333","citation_count":17,"is_preprint":false},{"pmid":"23717494","id":"PMC_23717494","title":"Glutathione S-transferase polymorphisms (GSTM1, GSTT1 and GSTP1) and their susceptibility to renal cell carcinoma: an evidence-based meta-analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23717494","citation_count":16,"is_preprint":false},{"pmid":"17221058","id":"PMC_17221058","title":"GSTT1 and GSTM1 polymorphism in cigarette smokers with head and neck squamous cell carcinoma.","date":"2006","source":"Brazilian journal of otorhinolaryngology","url":"https://pubmed.ncbi.nlm.nih.gov/17221058","citation_count":16,"is_preprint":false},{"pmid":"19330259","id":"PMC_19330259","title":"Polymorphism in CYP17, GSTM1 and the progesterone receptor genes and its relationship with mammographic density.","date":"2009","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/19330259","citation_count":16,"is_preprint":false},{"pmid":"28770368","id":"PMC_28770368","title":"Polymorphisms of GSTM1, GSTT1, GSTP1 genes and chromosomal aberrations in lung cancer patients.","date":"2017","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28770368","citation_count":16,"is_preprint":false},{"pmid":"23840148","id":"PMC_23840148","title":"CYP1A1, GSTM1, GSTT1 and NQO1 polymorphisms and colorectal adenomas in Japanese men.","date":"2013","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23840148","citation_count":15,"is_preprint":false},{"pmid":"19407363","id":"PMC_19407363","title":"GSTM1, GSTM3 and GSTT1 gene variants and risk of benign prostate hyperplasia in North India.","date":"2009","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/19407363","citation_count":15,"is_preprint":false},{"pmid":"24840051","id":"PMC_24840051","title":"Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, and GSTP1) in Egyptian pediatric patients with sickle cell disease.","date":"2014","source":"Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society","url":"https://pubmed.ncbi.nlm.nih.gov/24840051","citation_count":15,"is_preprint":false},{"pmid":"28198496","id":"PMC_28198496","title":"Association between GSTM1, GSTT1, and GSTP1 polymorphisms and gastric cancer risk, and their interactions with environmental factors.","date":"2017","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/28198496","citation_count":15,"is_preprint":false},{"pmid":"20957336","id":"PMC_20957336","title":"CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda.","date":"2010","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/20957336","citation_count":15,"is_preprint":false},{"pmid":"19664521","id":"PMC_19664521","title":"Genetic polymorphism of GSTT1 and GSTM1 and susceptibility to chronic obstructive pulmonary disease (COPD).","date":"2009","source":"Journal of critical care","url":"https://pubmed.ncbi.nlm.nih.gov/19664521","citation_count":15,"is_preprint":false},{"pmid":"19634112","id":"PMC_19634112","title":"Effect of polymorphisms in XRCC1, CCND1 and GSTM1 and tobacco exposure as risk modifier for oral leukoplakia.","date":"2009","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/19634112","citation_count":15,"is_preprint":false},{"pmid":"17005168","id":"PMC_17005168","title":"GSTT1 and GSTM1 allelic polymorphisms in head and neck cancer patients from Italian Lazio Region.","date":"2006","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17005168","citation_count":15,"is_preprint":false},{"pmid":"20049629","id":"PMC_20049629","title":"Analysis of GSTM1 and GSTT1 polymorphisms in circulating plasma DNA of lung cancer patients.","date":"2010","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20049629","citation_count":15,"is_preprint":false},{"pmid":"23077643","id":"PMC_23077643","title":"Association between GSTM1 and GSTT1 allelic variants and head and neck squamous cell cancinoma.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23077643","citation_count":14,"is_preprint":false},{"pmid":"23026209","id":"PMC_23026209","title":"The glutathione-S-transferase gene polymorphisms (GSTM1 and GSTT1) and idiopathic male infertility risk: a meta-analysis.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23026209","citation_count":14,"is_preprint":false},{"pmid":"21701824","id":"PMC_21701824","title":"Age-related macular degeneration and genetic polymorphisms of glutathione S-transferases M1 (GSTM1) and T1 (GSTT1).","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21701824","citation_count":14,"is_preprint":false},{"pmid":"35103568","id":"PMC_35103568","title":"GSTM1 and GSTT1 polymorphisms in healthy volunteers - a worldwide systematic review.","date":"2022","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35103568","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":60070,"output_tokens":3122,"usd":0.11352,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10539,"output_tokens":2699,"usd":0.060085,"stage2_stop_reason":"end_turn"},"total_usd":0.173605,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"The GSTM1 promoter contains a functional polymorphism that alters binding of the AP-2alpha transcription factor, resulting in reduced promoter activity and mRNA expression. A U-shaped (non-linear) association was identified: both GSTM1 null (no copies) and GSTM1 homozygous wild-type (+/+, two copies) are risk genotypes for breast cancer compared to heterozygous (+/-), suggesting that approximately 60-70% GSTM1 expression from one allele is sufficient for protection, and that both null activity and overactivity are disadvantageous.\",\n      \"method\": \"Case-control genotyping with copy-number distinction (null/heterozygous/homozygous), meta-analysis of 41 studies, reporter/promoter activity assay, electrophoretic mobility shift assay (AP-2alpha binding), and mRNA expression measurement\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (functional promoter assay, transcription factor binding, expression, population genetics) in a single lab; no independent replication of the mechanistic promoter finding reported in the corpus\",\n      \"pmids\": [\"19228880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GSTM1 copy number varies in a population-specific manner: more than 75% of Caucasian (CEU) HapMap samples carry a GSTM1 deletion, and none have two copies, whereas up to 25% of African (YRI) samples carry two copies of GSTM1. A previously reported HapMap SNP (rs366631) is a pseudo-SNP arising from sequence homology and the common GSTM1 upstream deletion; the upstream deletion can serve as a marker of GSTM1 gene deletion.\",\n      \"method\": \"Site-specific genotyping assays, copy-number variation (CNV) assays covering three GSTM1 regions, genome-wide association with expression in HapMap lymphoblastoid cell lines\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple CNV assays across gene regions, functional link to expression established by GWA; single lab, no independent replication cited\",\n      \"pmids\": [\"18948376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The GSTM1 promoter is significantly hypomethylated in ectopic and eutopic endometrium of ovarian endometriosis patients compared to controls, and this hypomethylation correlates negatively with GSTM1 mRNA expression. In vitro overexpression of GSTM1 in endometrial epithelial cells significantly increased cell viability and inhibited apoptosis following hormone treatment and withdrawal, demonstrating a functional anti-apoptotic role for GSTM1 in endometrial cells.\",\n      \"method\": \"Pyrosequencing of GSTM1 promoter methylation, RT-qPCR and immunohistochemistry for expression, primary endometrial epithelial cell culture with GSTM1 transfection, Cell Counting Kit-8 viability assay, flow cytometry for apoptosis\",\n      \"journal\": \"Human reproduction (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (bisulfite pyrosequencing, expression, functional overexpression in primary cells) in a single lab; anti-apoptotic function demonstrated by loss/gain in vitro but no independent replication\",\n      \"pmids\": [\"30989213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GSTM1 (glutathione S-transferase Mu 1) plays a protective role in lung inflammation; its expression is regulated by the NF-E2-related factor 2 (Nrf2) transcription factor pathway, and GSTM1 acts through interactions with other genes and environmental factors (especially air pollutants) to modulate pulmonary inflammatory responses. The GSTM1 null polymorphism (high prevalence in the population) is associated with increased risk of inflammatory lung diseases.\",\n      \"method\": \"Review synthesizing epidemiological, clinical, animal, and in vitro studies; no single primary experiment described in the abstract\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — review/synthesis paper; no primary experiment described in the abstract to directly establish Nrf2 regulation or specific inflammatory mechanism for GSTM1\",\n      \"pmids\": [\"22683820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"GSTM1 is involved in the metabolic detoxification of hydroquinone (a benzene metabolite): human lymphocytes from donors with the GSTM1 null genotype showed significantly higher micronucleus frequency upon hydroquinone treatment compared to GSTM1-present donors, indicating that GSTM1 status determines inter-individual differences in genotoxic DNA damage from hydroquinone exposure.\",\n      \"method\": \"Ex vivo treatment of human lymphocytes from genotyped donors with hydroquinone; micronucleus (MN) and sister-chromatid exchange (SCE) assays; genotyping of GSTM1, GSTT1, GSTP1\",\n      \"journal\": \"Environmental and molecular mutagenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay directly linking GSTM1 genotype to hydroquinone-induced DNA damage in human lymphocytes, two genotoxicity endpoints, single lab\",\n      \"pmids\": [\"15141365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"GSTM1 genotype modifies benzo[a]pyrene diol epoxide (BPDE)-DNA adduct levels in human lung: GSTM1*0 (null) individuals have higher (+)-anti-BPDE-DNA adduct levels in lung parenchyma than GSTM1-positive individuals. Carriers of the combined CYP1A1*2/GSTM1*0 genotype have the highest adduct levels, consistent with GSTM1 functioning to detoxify BPDE formed by CYP1A1-mediated activation of benzo[a]pyrene.\",\n      \"method\": \"Review and synthesis of published human lung tissue data measuring (+)-anti-BPDE-DNA adducts by immunoassay, stratified by CYP1A1 and GSTM1 genotype\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — convergent human tissue adduct data across multiple published studies; review synthesis rather than single primary experiment, but mechanistic inference is directly supported by adduct measurements\",\n      \"pmids\": [\"12507920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GSTM1 null genotype combined with NAT2 slow acetylator genotype synergistically increases carcinogen DNA adduct levels in human lung tissue by approximately 295% over baseline, compared to 150% for GSTM1 null alone and ~74% for NAT2 slow alone, demonstrating that GSTM1 and NAT2 act independently and interactively in protecting lung tissue from carcinogen adduct formation.\",\n      \"method\": \"(32)P-postlabeling assay for DNA adducts in lung and blood tissue from lung cancer patients; multiple regression analysis adjusting for confounders and other GST variants\",\n      \"journal\": \"Cancer epidemiology, biomarkers & prevention\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct tissue adduct measurement in human lung with quantitative genotype-stratified analysis; single study, single method for adduct quantification\",\n      \"pmids\": [\"20501762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"GSTM1 null genotype is associated with higher CYP1A2 activity (measured by caffeine phenotyping) compared to GSTM1*A,B individuals (10.2 vs. 8.5 under unexposed conditions; 15.0 vs. 12.3 under exposed conditions), indicating a gene-gene interaction whereby GSTM1 genotype influences in vivo CYP1A2 function.\",\n      \"method\": \"Caffeine phenotyping for CYP1A2 activity (urinary molar ratio), PCR-based GSTM1 and CYP1A1 genotyping in human volunteers under controlled dietary/smoking exposures\",\n      \"journal\": \"Mutation research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — indirect phenotyping assay, single lab, small samples, mechanism of interaction not directly elucidated\",\n      \"pmids\": [\"9202749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GSTM1 null genotype is associated with significantly increased urinary markers of oxidative DNA damage (8-OHdG) and lipid peroxidation (8-epi-PGF2α) in bladder cancer patients, and GSTM1-null combined with GSTA1-low activity genotype further amplifies oxidative DNA damage (8-OHdG), indicating GSTM1 functions as an antioxidant defense enzyme protecting against oxidative damage in bladder tissue.\",\n      \"method\": \"Enzyme immunoassay for 8-OHdG and 8-epi-PGF2α in urine of 80 TCC patients and 60 controls; PCR genotyping for GSTM1 deletion; PCR-RFLP for GSTA1 SNP\",\n      \"journal\": \"Redox report : communications in free radical research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — genotype-phenotype association using biomarker endpoints; single lab, single study, no direct enzymatic manipulation\",\n      \"pmids\": [\"23394311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In women with GSTM1 null genotype, arsenic exposure (measured by urinary arsenic) was significantly associated with increased urinary 8-OHdG (a marker of oxidative DNA damage), whereas no such association was seen in GSTM1-positive women, demonstrating that GSTM1 protects against arsenic-induced oxidative stress.\",\n      \"method\": \"Repeated-measures cohort study; urinary 8-OHdG measurement; arsenic exposure measured in urine, toenails, and drinking water; Taqman genotyping of GSTM1; random-effects Tobit regression\",\n      \"journal\": \"Environmental health : a global access science source\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — indirect biomarker association study; repeated measures add rigor but mechanism is inferred from genotype-exposure interaction, not direct enzyme assay\",\n      \"pmids\": [\"18053222\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GSTM1 encodes a glutathione S-transferase that catalyzes conjugation of glutathione with electrophilic compounds including polycyclic aromatic hydrocarbon metabolites (e.g., BPDE) and hydroquinone, thereby protecting cells from carcinogen-induced DNA adduct formation and oxidative DNA damage; its expression is regulated epigenetically (promoter methylation) and transcriptionally (AP-2alpha binding to a promoter polymorphism), and it exhibits a non-linear gene-dosage effect on cancer risk; in endometrial epithelial cells, GSTM1 overexpression directly inhibits apoptosis and promotes cell survival; the common homozygous deletion (null) genotype, which varies in frequency across populations, abolishes enzyme activity and increases susceptibility to DNA damage from environmental carcinogens and oxidative stress.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GSTM1 encodes a glutathione S-transferase that protects cells from electrophilic carcinogens and oxidative stress, and its activity is a major determinant of inter-individual susceptibility to DNA damage [#5, #6]. Functionally, GSTM1 detoxifies reactive metabolites: it conjugates the benzene metabolite hydroquinone, with null-genotype lymphocytes showing elevated genotoxic micronucleus frequency upon hydroquinone exposure [#4], and it neutralizes benzo[a]pyrene diol epoxide (BPDE) generated by CYP1A1, such that null individuals accumulate higher BPDE-DNA adducts in lung tissue [#5]. This protective role extends beyond electrophile conjugation to antioxidant defense, as the null genotype is associated with increased oxidative DNA damage markers (8-OHdG) under carcinogen and arsenic exposure [#8, #9]. GSTM1 acts within a network of xenobiotic-metabolizing genes, interacting independently and synergistically with NAT2 to limit carcinogen adduct formation [#6] and influencing in vivo CYP1A2 activity [#7]. GSTM1 expression is shaped by a promoter polymorphism that modulates AP-2alpha binding, producing a non-linear (U-shaped) gene-dosage effect in which both null and high-expression genotypes are disadvantageous [#0], and by promoter methylation, with hypomethylation-driven overexpression conferring an anti-apoptotic, pro-survival function in endometrial epithelial cells [#2]. The common homozygous deletion (null) genotype, whose frequency varies markedly across populations, abolishes enzyme activity [#1].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that GSTM1 genotype is not isolated but influences the activity of other xenobiotic-metabolizing enzymes, hinting at a coordinated detoxification network.\",\n      \"evidence\": \"Caffeine phenotyping for CYP1A2 activity with PCR genotyping in human volunteers under controlled exposures\",\n      \"pmids\": [\"9202749\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Indirect phenotyping assay with small samples\", \"Mechanism linking GSTM1 status to CYP1A2 activity not elucidated\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated that GSTM1 detoxifies CYP1A1-activated benzo[a]pyrene, with null genotype yielding higher BPDE-DNA adducts in lung, defining a concrete carcinogen substrate pathway.\",\n      \"evidence\": \"Synthesis of human lung tissue (+)-anti-BPDE-DNA adduct immunoassay data stratified by CYP1A1 and GSTM1 genotype\",\n      \"pmids\": [\"12507920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review synthesis rather than single controlled experiment\", \"Direct enzymatic conjugation of BPDE by GSTM1 not assayed in vitro here\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Provided direct functional evidence that GSTM1 protects against genotoxic damage from a specific substrate, hydroquinone, in primary human cells.\",\n      \"evidence\": \"Ex vivo hydroquinone treatment of genotyped human lymphocytes with micronucleus and sister-chromatid exchange assays\",\n      \"pmids\": [\"15141365\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genotype-based comparison rather than direct enzyme knockdown/rescue\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved the regulatory basis and dosage relationship of GSTM1 expression, identifying an AP-2alpha-binding promoter polymorphism and a non-linear U-shaped risk effect.\",\n      \"evidence\": \"Case-control copy-number genotyping, meta-analysis, reporter assay, EMSA for AP-2alpha binding, and mRNA measurement\",\n      \"pmids\": [\"19228880\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter mechanism not independently replicated\", \"Why high expression is disadvantageous not mechanistically explained\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the population-specific copy-number architecture of GSTM1 and corrected a spurious marker SNP, establishing the deletion as the functional driver of expression differences.\",\n      \"evidence\": \"Site-specific and CNV genotyping assays with genome-wide expression association in HapMap lymphoblastoid lines\",\n      \"pmids\": [\"18948376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No independent replication cited\", \"Functional consequence beyond expression not assessed in this work\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Quantified how GSTM1 cooperates with NAT2 to limit carcinogen DNA adduct burden, showing independent and synergistic protective contributions.\",\n      \"evidence\": \"32P-postlabeling DNA adduct measurement in human lung tissue with genotype-stratified multiple regression\",\n      \"pmids\": [\"20501762\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single study and single adduct quantification method\", \"Molecular basis of GSTM1-NAT2 synergy not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended GSTM1's protective role from electrophile conjugation to antioxidant defense, linking null genotype to elevated oxidative DNA damage in bladder tissue.\",\n      \"evidence\": \"Enzyme immunoassay for urinary 8-OHdG and 8-epi-PGF2alpha in bladder cancer patients with PCR genotyping\",\n      \"pmids\": [\"23394311\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Biomarker association without direct enzymatic manipulation\", \"Single lab/study\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Uncovered a non-detoxification cellular function: methylation-driven GSTM1 overexpression suppresses apoptosis and promotes survival in endometrial epithelial cells.\",\n      \"evidence\": \"Promoter methylation pyrosequencing, expression analysis, and GSTM1 overexpression in primary endometrial cells with viability and apoptosis assays\",\n      \"pmids\": [\"30989213\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Anti-apoptotic mechanism (effectors, signaling) not defined\", \"No independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GSTM1's enzymatic detoxification activity mechanistically connects to its anti-apoptotic, pro-survival role, and why high expression confers risk, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural or kinetic model linking conjugation activity to survival signaling\", \"Mechanism of the U-shaped dosage effect uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 5, 6]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}